Neuropsychological Assessment Battery-Screening Module (S-NAB): Performance in treatment-seeking cocaine users

Abstract

Background Cocaine use is associated with cognitive impairments, which can have a negative effect on treatment retention and drug use. Thus, there is an increasing demand for a screening cognitive battery can be used by clinicians to detect such impairments in cocaine patients so that treatment can be adapted to patients’ specific cognitive strengths and deficits. The Neuropsychological Assessment Battery-Screening Module (S-NAB) test for adults takes approximately 35–45 min to administer, and assesses attention, language, memory (verbal and visual), visual spatial reasoning, and executive functioning. Objective The purpose of this descriptive study was to present S-NAB score results for a sample of treatment seeking adult cocaine users to determine its potential utility for detecting cognitive impairments in this population. Methods In the present sample, 145 adult cocaine users participated in screening to enroll in an intervention to decrease cocaine use (59% male; 73.1% African American); screening included the S-NAB and self-report questionnaires. Results A substantial proportion of the sample (44%) met criteria for impairment, i.e. composite scores of one or more standard deviations below the mean. Furthermore, memory scores were significantly lower than language and spatial scores (p < 0.007). Conclusions The impairments detected by the S-NAB were generally consistent with those previously observed in samples of cocaine users completing other batteries, as well in other substance abusing samples completing the S-NAB. This suggests that the S-NAB can be considered an additional appropriate battery, as an alternative to other existing batteries, for assessment of the cognitive functioning of adult cocaine users.

Modified cognitive behavioral therapy (M-CBT) for cocaine dependence: Development of treatment for cognitively impaired users and results from a Stage 1 trial.

“…The Neurological Assessment Battery-Screening Module (NAB-SM) (Stern & White, 2003) was administered to determine patients’ level of cognitive functioning at baseline and at the end of treatment. The NAB-SM assesses five main areas of cognitive functioning: memory, attention, language, spatial reasoning, and executive functioning (Cannizzaro et al, 2014; Stern & White, 2003). The NAB-SM scores are corrected for age, gender, and education level.…”

Adolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods

“…Human and preclinical evidence demonstrates that other illicit substances are linked with neurocognitive deficits in adolescents and young adults, including cocaine ( Cannizzaro et al, 2014 ; Nuijten et al, 2016 ; Kaag et al, 2016 , Kaag et al, 2014 ; Marhe and Franken, 2014 ; Rose-Jacobs et al, 2011 ; Lundqvist, 2010 ; Meade et al, 2015 ; Fernández-Serrano et al, 2010 ; Sim et al, 2007 ; Rahman and Clarke, 2005 ; Kober et al, 2016 ; Verdejo-Garcia et al, 2015 ; Moreno-López et al, 2015 ; Ide et al, 2014 ; Tau et al, 2014 ; Albein-Urios et al, 2014 ; Ernst et al, 2000 ; Mayer et al, 2013 ), methamphetamine ( Buck and Siegel, 2015 ; Cuzen et al, 2015 ; King et al, 2010 ; Scott et al, 2007 ), MDMA or ecstasy ( Medina et al, 2005 ; Medina and Shear, 2007 ; Costa et al, 2014 ; Price et al, 2014 ; Downey et al, 2015 ; Halpern et al, 2011 ; Scholey et al, 2011 ; McCann et al, 2014 , McCann et al, 2008 ; Jager et al, 2008 ; de Win et al, 2008 ), inhalants ( Takagi et al, 2011a , Takagi et al, 2011b , Takagi et al, 2014 ; Scott and Scott, 2012 , Scott and Scott, 2014 ), heroin ( Zeng et al, 2013 ; Lundqvist, 2010 ; Ornstein et al, 2000 ; Fernández-Serrano et al, 2010 ), cathinones ( Albertson et al, 2016 ; Patrick et al, 2016 ), ketamine ( Chen et al, 2015 ; Nagy et al, 2015 ; Tang et al, 2013 ; Sun et al, 2014 ; Morgan et al, 2012a <...>…”

“…Human and preclinical evidence demonstrates that other illicit substances are linked with neurocognitive deficits in adolescents and young adults, including cocaine (Cannizzaro et al, 2014; Nuijten et al, 2016; Kaag et al, 2016, 2014; Marhe and Franken, 2014; Rose-Jacobs et al, 2011; Lundqvist, 2010; Meade et al, 2015; Fernández-Serrano et al, 2010; Sim et al, 2007; Rahman and Clarke, 2005; Kober et al, 2016; Verdejo-Garcia et al, 2015; Moreno-López et al, 2015; Ide et al, 2014; Tau et al, 2014; Albein-Urios et al, 2014; Ernst et al, 2000; Mayer et al, 2013), methamphetamine (Buck and Siegel, 2015; Cuzen et al, 2015; King et al, 2010; Scott et al, 2007), MDMA or ecstasy (Medina et al, 2005; Medina and Shear, 2007; Costa et al, 2014; Price et al, 2014; Downey et al, 2015; Halpern et al, 2011; Scholey et al, 2011; McCann et al, 2014, 2008; Jager et al, 2008; de Win et al, 2008), inhalants (Takagi et al, 2011a, 2011b, 2014; Scott and Scott, 2012, 2014), heroin (Zeng et al, 2013; Lundqvist, 2010; Ornstein et al, 2000; Fernández-Serrano et al, 2010), cathinones (Albertson et al, 2016; Patrick et al, 2016), ketamine (Chen et al, 2015; Nagy et al, 2015; Tang et al, 2013; Sun et al, 2014; Morgan et al, 2012a), gamma hydroxybutyrate (Johansson et al, 2014; Sircar et al, 2008; Youn et al, 2015), hallucinogens (lysergic acid diethylamide, phencyclidine, peyote, mescaline, N,N- dimethyltryptamine, alpha-methyltryptamine, or 5-methoxy-N,N-diisopropyltryptamine, psilocybin, or salvia) (Compton et al, 2011; Noworyta-Sokołowska et al, 2016; Graham et al, 2010, 2012; Halpern et al, 2005; Carstairs and Cantrell, 2010; Fickenscher et al, 2006; Mahendran et al, 2016; Ranganathan et al, 2012), and anabolic steroids (Wallin-…”

Validation study of the Neuropsychological Assessment Battery Czech version

“…Validita baterie byla prověřena i v nezávislých studiích v klinické praxi u pacientů s epilepsií (Daniels, 2011), pacientů s traumatickým poškozením mozku (Zgaljardic & Temple, 2010a) a po CMP (Pulsipher, Stricker, Sadek, & Haaland, 2013). Zároveň byla pozornost věnována i ověření validity a reliability jak Screeningového modulu u pacientů s traumatickým poškozením mozku (Temple et al, 2009;Zgaljardic & Temple, 2010b) či u uživatelů návykových látek (Cannizzaro, Elliott, Stohl, Hasin, & Aharonovich, 2014;Grohman & Fals-Stewart, 2004), tak u některých samostatných subtestů (Gavett et al, 2016;Hill, Strutt, Uber--Zak, Fogel, & Ropacki, 2012;Yochim, Kane, & Mueller, 2009;Brown et al, 2005).…”